More on BAYZF
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $56.50 |
|
|||
| Open | $56.50 | ||||
| 52 Wk High | $135.00 | ||||
| 52 Wk Low | $94.95 | ||||
| Day High | $56.50 | ||||
| Day Low | $56.50 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 17 | ||||
- Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
- FDA grants Bayer's HYRNUO accelerated approval as first-line NSCLC therapy
- U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
- Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026
- Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
- LYNKUET® (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer
- One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin
- New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
- Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
- Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming
Entities mentioned with BAYZF
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- S1 | View Related Stories »
- Tesla | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
